202 related articles for article (PubMed ID: 11841415)
1. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin.
Crowther MA; Berry LR; Monagle PT; Chan AK
Br J Haematol; 2002 Jan; 116(1):178-86. PubMed ID: 11841415
[TBL] [Abstract][Full Text] [Related]
2. Protamine neutralisation of low molecular weight heparins and their oligosaccharide components.
Schroeder M; Hogwood J; Gray E; Mulloy B; Hackett AM; Johansen KB
Anal Bioanal Chem; 2011 Jan; 399(2):763-71. PubMed ID: 20922518
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of low-molecular-weight heparin reversal by platelet factor 4.
Fiore MM; Mackie IM
Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682
[TBL] [Abstract][Full Text] [Related]
4. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
[TBL] [Abstract][Full Text] [Related]
5. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity.
Chang LC; Liang JF; Lee HF; Lee LM; Yang VC
AAPS PharmSci; 2001; 3(3):E18. PubMed ID: 11741269
[TBL] [Abstract][Full Text] [Related]
6. Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo.
Schick BP; Maslow D; Moshinski A; San Antonio JD
Blood; 2004 Feb; 103(4):1356-63. PubMed ID: 14576044
[TBL] [Abstract][Full Text] [Related]
7. Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa.
Lewis J; Iqbal O; Jeske W; Hoppensteadt D; Siddiqui F; Fareed J
Clin Appl Thromb Hemost; 2022; 28():10760296221099934. PubMed ID: 35535398
[TBL] [Abstract][Full Text] [Related]
8. A [+18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low-molecular-weight heparin anticoagulation.
Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Tejwani S; Hulin MS; Stanley JC
J Surg Res; 1996 Jun; 63(1):280-6. PubMed ID: 8661211
[TBL] [Abstract][Full Text] [Related]
9. Neutralization of enoxaparine-induced bleeding by protamine sulfate.
Van Ryn-McKenna J; Cai L; Ofosu FA; Hirsh J; Buchanan MR
Thromb Haemost; 1990 Apr; 63(2):271-4. PubMed ID: 2163553
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization.
Chang LC; Lee HF; Yang Z; Yang VC
AAPS PharmSci; 2001; 3(3):E17. PubMed ID: 11741268
[TBL] [Abstract][Full Text] [Related]
11. Neutralization of low molecular weight heparin by polybrene prevents thromboxane release and severe pulmonary hypertension in awake sheep.
Montalescot G; Zapol WM; Carvalho A; Robinson DR; Torres A; Lowenstein E
Circulation; 1990 Nov; 82(5):1754-64. PubMed ID: 2171807
[TBL] [Abstract][Full Text] [Related]
12. Chemical and pharmacological aspects of neutralization of heparins from different animal sources by protamine.
Glauser BF; Santos GRC; Silva JD; Tovar AMF; Pereira MS; Vilanova E; Mourão PAS
J Thromb Haemost; 2018 Sep; 16(9):1789-1799. PubMed ID: 29968421
[TBL] [Abstract][Full Text] [Related]
13. [Reversal for heparins and new anticoagulant treatments].
Kortchinsky T; Vigué B; Samama CM
Ann Fr Anesth Reanim; 2013 Jan; 32(1):37-49. PubMed ID: 23273505
[TBL] [Abstract][Full Text] [Related]
14. Protamine reversal of low molecular weight heparin: clinically effective?
van Veen JJ; Maclean RM; Hampton KK; Laidlaw S; Kitchen S; Toth P; Makris M
Blood Coagul Fibrinolysis; 2011 Oct; 22(7):565-70. PubMed ID: 21959588
[TBL] [Abstract][Full Text] [Related]
15. HEMA-Lysine-Based Cryogels for Highly Selective Heparin Neutralization.
Mecca T; Spitaleri F; La Spina R; Gioria S; Giglio V; Cunsolo F
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928208
[TBL] [Abstract][Full Text] [Related]
16. In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative.
Kuziej J; Litinas E; Hoppensteadt DA; Liu D; Walenga JM; Fareed J; Jeske W
Clin Appl Thromb Hemost; 2010 Aug; 16(4):377-86. PubMed ID: 20460347
[TBL] [Abstract][Full Text] [Related]
17. Determination of low-molecular-weight heparins and their binding to protamine and a protamine analog using polyion-sensitive membrane electrodes.
Ramamurthy N; Baliga N; Wakefield TW; Andrews PC; Yang VC; Meyerhoff ME
Anal Biochem; 1999 Jan; 266(1):116-24. PubMed ID: 9887220
[TBL] [Abstract][Full Text] [Related]
18. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J
Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
[TBL] [Abstract][Full Text] [Related]
19. Low molecular weight protamine (LMWP): a nontoxic protamine substitute and an effective cell-penetrating peptide.
He H; Ye J; Liu E; Liang Q; Liu Q; Yang VC
J Control Release; 2014 Nov; 193():63-73. PubMed ID: 24943246
[TBL] [Abstract][Full Text] [Related]
20. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model.
Lee LM; Chang LC; Wrobleski S; Wakefield TW; Yang VC
AAPS PharmSci; 2001; 3(3):E19. PubMed ID: 11741270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
